The Korean journal of internal medicine

  • 제33권2호
  • /
  • Pages.256-276
  • /
  • 2018
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea

  • Cho, Sung-Yeon (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, Hyeon-Jeong (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, Dong-Gun (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
  • 투고 : 2018.02.12
  • 심사 : 2018.02.18
  • 발행 : 2018.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic malignancies, immune deficiencies, or genetic diseases, ect. Recently, the number of HSCTs performed in Korea has increased and the outcomes have improved. However, infectious complications account for most of the morbidity and mortality after HSCT. Post-HSCT infectious complications are usually classified according to the time after HSCT: pre-engraftment, immediate post-engraftment, and late post-engraftment period. In addition, the types and risk factors of infectious complications differ according to the stem cell source, donor type, conditioning intensity, region, prophylaxis strategy, and comorbidities, such as graft-versus-host disease and invasive fungal infection. In this review, we summarize infectious complications after HSCT, focusing on the Korean perspectives.

키워드

참고문헌

  1. Lee DG. Common infectious diseases in hematopoietic stem cell transplant recipients. Korean J Med 2013;84:158-167. https://doi.org/10.3904/kjm.2013.84.2.158
  2. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am 2011;25:101-116. https://doi.org/10.1016/j.hoc.2010.11.008
  3. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-1238. https://doi.org/10.1016/j.bbmt.2009.06.019
  4. Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis 2011;53:798-806. https://doi.org/10.1093/cid/cir492
  5. Lee JW, Kim CC. The activity of hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 2008;42 Suppl 1:S92-S95. https://doi.org/10.1038/bmt.2008.127
  6. Yoo JH, Lee DG, Choi SM, et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 2004;34:497-504. https://doi.org/10.1038/sj.bmt.1704636
  7. Park SH, Choi SM, Lee DG, et al. Current trends of infectious complications following hematopoietic stem cell transplantation in a single center. J Korean Med Sci 2006;21:199-207.
  8. Kim SH, Kee SY, Lee DG, et al. Infectious complications following allogeneic stem cell transplantation: reduced- intensity vs. myeloablative conditioning regimens. Transpl Infect Dis 2013;15:49-59. https://doi.org/10.1111/tid.12003
  9. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012;19:324-335. https://doi.org/10.1097/MOH.0b013e328353bc7d
  10. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010;115:3861-3868. https://doi.org/10.1182/blood-2009-12-234096
  11. Ogonek J, Kralj Juric M, Ghimire S, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol 2016;7:507.
  12. Dropulic LK, Lederman HM. Overview of infections in the immunocompromised host. In: Hayden RT, Carroll KC, Tang YW, Wolk DM, eds. Diagnostic Microbiology of the Immunocompromised Host. 1st ed. Washington, DC: ASM Press, 2009:3-43.
  13. Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 2011;26:220-252. https://doi.org/10.3904/kjim.2011.26.2.220
  14. Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother 2016;22:505-514. https://doi.org/10.1016/j.jiac.2016.05.006
  15. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011;52:e56-e93. https://doi.org/10.1093/cid/cir073
  16. EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 1990;26:569-574. https://doi.org/10.1016/0277-5379(90)90079-9
  17. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998;41 Suppl D:13-24.
  18. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014;68:321-331. https://doi.org/10.1016/j.jinf.2013.12.006
  19. Jun HX, Zhixiang S, Chun W, et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents 2005;26 Suppl 2:S128-S132. https://doi.org/10.1016/j.ijantimicag.2005.08.007
  20. Choi SM, Lee DG, Park YH, et al. Infections in patients with acute leukemia: comparison of induction chemotherapy group and reinduction chemotherapy group. Infect Chemother 2003;35:78-85.
  21. Kim HB, Park SW, Kim US, et al. Infections in patients with acute leukemia (1993-1996). Korean J Hematol 1999;34:359-365.
  22. Kwon JC, Kim SH, Choi JK, et al. Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center. Infect Chemother 2013;45:51-61. https://doi.org/10.3947/ic.2013.45.1.51
  23. Hammarstrom V, Pauksen K, Svensson H, et al. Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients. Transplantation 2000;69:1582-1586.
  24. Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence 2016;7:280-297. https://doi.org/10.1080/21505594.2016.1156821
  25. Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013;19:474-479. https://doi.org/10.1111/j.1469-0691.2012.03879.x
  26. Kim SH, Kwon JC, Choi SM, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum ${\beta}$-lactamase production and its impact on outcome. Ann Hematol 2013;92:533-541. https://doi.org/10.1007/s00277-012-1631-y
  27. Prabhash K, Medhekar A, Ghadyalpatil N, et al. Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. Indian J Cancer 2010;47:184-188. https://doi.org/10.4103/0019-509X.63019
  28. Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015;50:282-288. https://doi.org/10.1038/bmt.2014.231
  29. Gedik H, Simsek F, Kanturk A, et al. Bloodstream infections in patients with hematological malignancies: which is more fatal. Cancer or resistant pathogens? Ther Clin Risk Manag 2014;10:743-752.
  30. Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect 2014;20:1357-1362. https://doi.org/10.1111/1469-0691.12747
  31. Kim SB, Min YH, Cheong JW, et al. Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scand J Infect Dis 2014;46:81-88. https://doi.org/10.3109/00365548.2013.857042
  32. Cho SY, Lee DG, Choi SM, et al. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. BMC Infect Dis 2013;13:504. https://doi.org/10.1186/1471-2334-13-504
  33. Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011;24:545-553. https://doi.org/10.1097/QCO.0b013e32834cf054
  34. Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer 2009;101 Suppl 1:S11-S14. https://doi.org/10.1038/sj.bjc.6605270
  35. Neumann S, Krause SW, Maschmeyer G, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013;92:433-442. https://doi.org/10.1007/s00277-013-1698-0
  36. Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum beta- lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control 2005;33:326-332. https://doi.org/10.1016/j.ajic.2005.03.009
  37. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Pseudomonas aeruginosa: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-1171. https://doi.org/10.1086/319757
  38. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163-167. https://doi.org/10.1007/s10096-003-1084-2
  39. Craig M, Cumpston AD, Hobbs GR, Devetten MP, Sarwari AR, Ericson SG. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant 2007;39:477-482. https://doi.org/10.1038/sj.bmt.1705591
  40. Cumpston A, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit. Transpl Infect Dis 2013;15:142-149. https://doi.org/10.1111/tid.12035
  41. von Baum H, Sigge A, Bommer M, et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006;58:891-894. https://doi.org/10.1093/jac/dkl320
  42. Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect 2018;76:20-37. https://doi.org/10.1016/j.jinf.2017.10.009
  43. Gea-Banacloche J. Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2013;2013:414-422.
  44. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013;98:1826-1835. https://doi.org/10.3324/haematol.2013.091025
  45. Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2012;96:748-757. https://doi.org/10.1007/s12185-012-1210-y
  46. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007;45:1161-1170. https://doi.org/10.1086/522189
  47. Choi JK, Cho SY, Yoon SS, et al. Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of "RISK" Study. Biol Blood Marrow Transplant 2017;23:1773-1779. https://doi.org/10.1016/j.bbmt.2017.06.012
  48. National Comprehensive Cancer Network. National Comprehensive Cancer Network clinical practice guidelines in oncology: prevention and treatment of cancer-related infections. Version 1. 2018 [Internet]. Fort Washington (PA): NCCN, c2018 [cited 2018 Feb 12]. Available from: https://www.nccn.org/professionals/physician_gls/ recently_updated.aspx.
  49. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 2010;50:405-415. https://doi.org/10.1086/649879
  50. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med 2015;373:1445-1456. https://doi.org/10.1056/NEJMra1315399
  51. Pappas PG, Kauffman CA, Andes DR, et al. clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-e50. https://doi.org/10.1093/cid/ciw103
  52. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010;24:257-272. https://doi.org/10.1016/j.idc.2010.01.010
  53. Marchetti O, Lamoth F, Mikulska M, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012;47:846-854. https://doi.org/10.1038/bmt.2011.178
  54. Hsu LY, Lee DG, Yeh SP, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. Clin Microbiol Infect 2015;21:594.
  55. Bergeron A, Porcher R, Sulahian A, et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 2012;119:1831-1837. https://doi.org/10.1182/blood-2011-04-351601
  56. Kim SH, Lee DG, Kwon JC, et al. Clinical impact of cytochrome P450 2C19 genotype on the treatment of invasive aspergillosis under routine therapeutic drug monitoring of voriconazole in a Korean population. Infect Chemother 2013;45:406-414. https://doi.org/10.3947/ic.2013.45.4.406
  57. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016;387:760-769. https://doi.org/10.1016/S0140-6736(15)01159-9
  58. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017;102:433-444. https://doi.org/10.3324/haematol.2016.152900
  59. Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009;27:3398-3409. https://doi.org/10.1200/JCO.2008.20.1178
  60. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3. 2009 update. Bone Marrow Transplant 2011;46:709-718. https://doi.org/10.1038/bmt.2010.175
  61. Kim SB, Cho SY, Lee DG, et al. Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: a 5-year retrospective cohort study. Med Mycol 2017;55:237-245.
  62. Park SY, Yoon JA, Kim SH. Voriconazole-refractory invasive aspergillosis. Korean J Intern Med 2017;32:805-812. https://doi.org/10.3904/kjim.2017.109
  63. Cho SY, Lee DG, Choi JK, et al. Characteristics of culture- positive invasive pulmonary aspergillosis in patients with hematologic diseases: comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species. Medicine (Baltimore) 2017;96:e8841. https://doi.org/10.1097/MD.0000000000008841
  64. Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016;71:2397-2404. https://doi.org/10.1093/jac/dkw157
  65. Lee HY, Kang HS, Lee HY, et al. Clinical significance of positive Pneumocystis jirovecii polymerase chain reaction in non-human immunodeficiency virus immunocompromised patients in a real practice. Korean J Intern Med 2017;32:478-485. https://doi.org/10.3904/kjim.2015.340
  66. Fan LC, Lu HW, Cheng KB, Li HP, Xu JF. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review. PLoS One 2013;8:e73099. https://doi.org/10.1371/journal.pone.0073099
  67. Lu Y, Ling G, Qiang C, et al. PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol 2011;49:4361-4363. https://doi.org/10.1128/JCM.06066-11
  68. Alanio A, Hauser PM, Lagrou K, et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016;71:2386-2396. https://doi.org/10.1093/jac/dkw156
  69. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta- analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052-1059. https://doi.org/10.4065/82.9.1052
  70. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007;(3):CD005590.
  71. Cordonnier C, Cesaro S, Maschmeyer G, et al. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016;71:2379-2385. https://doi.org/10.1093/jac/dkw155
  72. Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014;44:1350-1363. https://doi.org/10.1111/imj.12599
  73. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132:3-12. https://doi.org/10.1111/j.1365-2141.2005.05789.x
  74. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011;121:1673-1680. https://doi.org/10.1172/JCI45449
  75. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-1097. https://doi.org/10.1086/339329
  76. Ljungman P, Reusser P, de la Camara R, et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004;33:1075-1081. https://doi.org/10.1038/sj.bmt.1704505
  77. Choi SM, Lee DG, Park SH, et al. Characteristics of cytomegalovirus diseases among hematopoietic stem cell transplant recipients: a 10-year experience at an university hospital in Korea. Infect Chemother 2009;41:9-19. https://doi.org/10.3947/ic.2009.41.1.9
  78. Jeon S, Lee WK, Lee Y, Lee DG, Lee JW. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. Ophthalmology 2012;119:1892-1898. https://doi.org/10.1016/j.ophtha.2012.03.032
  79. Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 2016;127:2427-2438. https://doi.org/10.1182/blood-2015-11-679639
  80. Kim T, Lee YM, Lee SO, et al. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. Korean J Intern Med 2016;31:961-970. https://doi.org/10.3904/kjim.2015.079
  81. Lee HY, Rhee CK, Choi JY, Lee HY, Lee JW, Lee DG. Diagnosis of cytomegalovirus pneumonia by quantitative polymerase chain reaction using bronchial washing fluid from patients with hematologic malignancies. Oncotarget 2017;8:39736-39745.
  82. Choi SM, Lee DG, Lim J, et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. J Korean Med Sci 2009;24:571-578. https://doi.org/10.3346/jkms.2009.24.4.571
  83. Choi SM, Lee DG, Choi JH, et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea. Int J Hematol 2005;81:69-74. https://doi.org/10.1532/IJH97.A30402
  84. Cho BS, Yahng SA, Kim JH, et al. Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy. Ann Hematol 2013;92:497-504. https://doi.org/10.1007/s00277-012-1632-x
  85. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 2017;377:2433-2444. https://doi.org/10.1056/NEJMoa1706640
  86. Khanna R. Immune monitoring of infectious complications in transplant patients: an important step towards improved clinical management. J Clin Microbiol 2018 Jan 17 [Epub]. https://doi.org/10.1128/JCM.02009-17.
  87. Yong MK, Cameron PU, Slavin M, et al. Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation. J Infect Dis 2017;215:1684-1694. https://doi.org/10.1093/infdis/jix192
  88. Jung J, Lee HJ, Kim SM, et al. Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients. J Clin Virol 2017;87:5-11. https://doi.org/10.1016/j.jcv.2016.11.012
  89. Kim SH, Lee HS, Lee HJ, et al. Clinical applications of interferon-${\gamma}$ releasing assays for cytomegalovirus to differentiate cytomegalovirus disease from bystander activation: a pilot proof-of-concept study. Korean J Intern Med 2017;32:900-909. https://doi.org/10.3904/kjim.2015.354
  90. Kim SH, Lee HJ, Kim SM, et al. Diagnostic usefulness of cytomegalovirus (CMV)-specific T cell immunity in predicting CMV infection after kidney transplantation: a pilot proof-of-concept study. Infect Chemother 2015;47:105-110. https://doi.org/10.3947/ic.2015.47.2.105
  91. Lee H, Park KH, Ryu JH, et al. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON- CMV assay in seropositive kidney transplant recipients. PLoS One 2017;12:e0189488. https://doi.org/10.1371/journal.pone.0189488
  92. Han SH. Immunological prediction of cytomegalovirus (CMV) replication risk in solid organ transplantation recipients: approaches for regulating the targeted anti-CMV prevention strategies. Infect Chemother 2017;49:161-175. https://doi.org/10.3947/ic.2017.49.3.161
  93. Park SH, Choi SM, Lee DG, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis 2009;11:413-423. https://doi.org/10.1111/j.1399-3062.2009.00414.x
  94. Gilbert C, Roy J, Belanger R, et al. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother 2001;45:3669-3671. https://doi.org/10.1128/AAC.45.12.3669-3671.2001
  95. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010;65:2628-2640. https://doi.org/10.1093/jac/dkq368
  96. Shmueli E, Or R, Shapira MY, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis 2014;209:557-561. https://doi.org/10.1093/infdis/jit475
  97. El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood 2016;128:2624-2636. https://doi.org/10.1182/blood-2016-06-688432
  98. Kang CI, Choi CM, Park TS, Lee DJ, Oh MD, Choe KW. Incidence of herpes zoster and seroprevalence of varicella- zoster virus in young adults of South Korea. Int J Infect Dis 2008;12:245-247. https://doi.org/10.1016/j.ijid.2007.08.002
  99. Kim YH, Hwang JY, Lee KM, et al. Seroepidemiologic survey of varicella-zoster virus in Korean adults using glycoprotein enzyme immunoassay and fluorescent antibody to membrane antigen test. Ann Dermatol 2011;23:39-43. https://doi.org/10.5021/ad.2011.23.1.39
  100. Choi WS, Noh JY, Huh JY, et al. Seroprevalence of varicella- zoster virus in Korea. J Med Virol 2010;82:2123-2126. https://doi.org/10.1002/jmv.21917
  101. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009;43:757-770. https://doi.org/10.1038/bmt.2008.386
  102. Kim DH, Kumar D, Messner HA, et al. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant 2008;22:770-779. https://doi.org/10.1111/j.1399-0012.2008.00877.x
  103. Seo HM, Kim YS, Bang CH, et al. Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Antiviral Res 2017;140:106-115. https://doi.org/10.1016/j.antiviral.2017.01.011
  104. Park SH, Choi SM, Lee DG, et al. Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea. J Korean Med Sci 2006;21:259-264. https://doi.org/10.3346/jkms.2006.21.2.259
  105. Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 2016;101:803-811. https://doi.org/10.3324/haematol.2016.144428
  106. Kim YJ, Kim DW, Lee DG, et al. Human herpesvirus-6 as a possible cause of encephalitis and hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Leukemia 2002;16:958-959. https://doi.org/10.1038/sj.leu.2402403
  107. Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant 2008;41:11-18. https://doi.org/10.1038/sj.bmt.1705886
  108. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006;43:331-339. https://doi.org/10.1086/505498
  109. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115-123. https://doi.org/10.1002/jmv.10450
  110. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009;5:e1000363. https://doi.org/10.1371/journal.ppat.1000363
  111. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009;199:837-846. https://doi.org/10.1086/597126
  112. Rinaldo CH, Tylden GD, Sharma BN. The human polyomavirus BK (BKPyV): virological background and clinical implications. APMIS 2013;121:728-745. https://doi.org/10.1111/apm.12134
  113. Cesaro S, Dalianis T, Hanssen Rinaldo C, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother 2018;73:12-21. https://doi.org/10.1093/jac/dky158
  114. Erard V, Kim HW, Corey L, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood 2005;106:1130-1132. https://doi.org/10.1182/blood-2004-12-4988
  115. Cesaro S, Tridello G, Pillon M, et al. A prospective study on the predictive value of plasma BK virus-DNA load for hemorrhagic cystitis in pediatric patients after stem cell transplantation. J Pediatric Infect Dis Soc 2015;4:134-142. https://doi.org/10.1093/jpids/piu043
  116. Gaziev J, Paba P, Miano R, et al. Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir. Biol Blood Marrow Transplant 2010;16:662-671. https://doi.org/10.1016/j.bbmt.2009.12.009
  117. Koskenvuo M, Dumoulin A, Lautenschlager I, et al. BK polyomavirus-associated hemorrhagic cystitis among pediatric allogeneic bone marrow transplant recipients: treatment response and evidence for nosocomial transmission. J Clin Virol 2013;56:77-81. https://doi.org/10.1016/j.jcv.2012.09.003
  118. Kwon HJ, Kang JH, Lee JW, Chung NG, Kim HK, Cho B. Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single-center experience. Transpl Infect Dis 2013;15:569-574. https://doi.org/10.1111/tid.12136
  119. Faraci M, Cuzzubbo D, Lanino E, et al. Low dosage cidofovir without probenecid as treatment for BK virus hamorrhagic cystitis after hemopoietic stem cell transplant. Pediatr Infect Dis J 2009;28:55-57. https://doi.org/10.1097/INF.0b013e3181812cb9
  120. Ganguly N, Clough LA, Dubois LK, et al. Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach. Transpl Infect Dis 2010;12:406-411. https://doi.org/10.1111/j.1399-3062.2010.00513.x
  121. Lee SS, Ahn JS, Jung SH, et al. Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation. Korean J Intern Med 2015;30:212-218. https://doi.org/10.3904/kjim.2015.30.2.212
  122. Savona MR, Newton D, Frame D, Levine JE, Mineishi S, Kaul DR. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant 2007;39:783-787. https://doi.org/10.1038/sj.bmt.1705678
  123. Tylden GD, Hirsch HH, Rinaldo CH. Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells. Antimicrob Agents Chemother 2015;59:3306-3316. https://doi.org/10.1128/AAC.00238-15
  124. Weigt SS, Gregson AL, Deng JC, Lynch JP 3rd, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med 2011;32:471-493. https://doi.org/10.1055/s-0031-1283286
  125. Kumar D, Humar A. Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am 2010;24:395-412. https://doi.org/10.1016/j.idc.2010.01.007
  126. Ahn MY, Choi SH, Chung JW, Kim HR. Utilization of the respiratory virus multiplex reverse transcription-polymerase chain reaction test for adult patients at a Korean tertiary care center. Korean J Intern Med 2015;30:96-103. https://doi.org/10.3904/kjim.2015.30.1.96
  127. Hong KW, Choi SM, Lee DG, et al. Lower respiratory tract diseases caused by common respiratory viruses among stem cell transplantation recipients: a single center experience in Korea. Yonsei Med J 2017;58:362-369. https://doi.org/10.3349/ymj.2017.58.2.362
  128. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011;117:2755-2763. https://doi.org/10.1182/blood-2010-08-263400
  129. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013;56:258-266. https://doi.org/10.1093/cid/cis844
  130. Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 2012;119:2738-2745. https://doi.org/10.1182/blood-2011-08-371112
  131. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001;98:573-578. https://doi.org/10.1182/blood.V98.3.573
  132. Ljungman P, de la Camara R, Perez-Bercoff L, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011;96:1231-1235. https://doi.org/10.3324/haematol.2011.041913
  133. Schnell D, Mayaux J, de Bazelaire C, et al. Risk factors for pneumonia in immunocompromised patients with influenza. Respir Med 2010;104:1050-1056. https://doi.org/10.1016/j.rmed.2010.01.021
  134. Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis 2013;15:219-232. https://doi.org/10.1111/tid.12054
  135. Parody R, Rabella N, Martino R, et al. Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies. Am J Hematol 2007;82:807-811. https://doi.org/10.1002/ajh.20974
  136. Gutman JA, Peck AJ, Kuypers J, Boeckh M. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. Bone Marrow Transplant 2007;40:809-811. https://doi.org/10.1038/sj.bmt.1705827
  137. Dignan FL, Clark A, Aitken C, et al. BCSH/BSBMT/ UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. Br J Haematol 2016;173:380-393. https://doi.org/10.1111/bjh.14027
  138. Baek JH, Seo YB, Choi WS, et al. Guideline on the prevention and control of seasonal influenza in healthcare setting. Korean J Intern Med 2014;29:265-280. https://doi.org/10.3904/kjim.2014.29.2.265
  139. Choi WS, Lee J, Lee HY, et al. Clinical practice guideline for antiviral treatment and chemoprophylaxis of seasonal influenza. Infect Chemother 2012;44:233-249. https://doi.org/10.3947/ic.2012.44.4.233
  140. von Lilienfeld-Toal M, Berger A, Christopeit M, et al. Community acquired respiratory virus infections in cancer patients-guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology. Eur J Cancer 2016;67:200-212. https://doi.org/10.1016/j.ejca.2016.08.015
  141. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood 2014;123:3263-3268. https://doi.org/10.1182/blood-2013-12-541359
  142. de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007;45:1019-1024. https://doi.org/10.1086/521912
  143. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS- 5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014;371:711-722. https://doi.org/10.1056/NEJMoa1401184
  144. Choi WS, Baek JH, Seo YB, et al. Severe influenza treatment guideline. Korean J Intern Med 2014;29:132-147. https://doi.org/10.3904/kjim.2014.29.1.132
  145. Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 2012;40:990-1013. https://doi.org/10.1183/09031936.00000712
  146. Lee HJ, Lee DG, Choi SM, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: high incidence compared with general population. PLoS One 2017;12:e0173250. https://doi.org/10.1371/journal.pone.0173250
  147. Fan WC, Liu CJ, Hong YC, et al. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. Int J Tuberc Lung Dis 2015;19:58-64. https://doi.org/10.5588/ijtld.14.0301
  148. Al-Anazi KA, Al-Jasser AM, Alsaleh K. Infections caused by mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation. Front Oncol 2014;4:231.
  149. Lee J, Lee MH, Kim WS, et al. Tuberculosis in hematopoietic stem cell transplant recipients in Korea. Int J Hematol 2004;79:185-188. https://doi.org/10.1532/IJH97.A10219
  150. Tsigrelis C, Ljungman P. Vaccinations in patients with hematological malignancies. Blood Rev 2016;30:139-147. https://doi.org/10.1016/j.blre.2015.10.001
  151. Chong PP, Avery RK. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clin Ther 2017;39:1581-1598. https://doi.org/10.1016/j.clinthera.2017.07.005
  152. Lee DG. Vaccination of hematopoietic stem cell transplantation recipients: perspective in Korea. Infect Chemother 2013;45:272-282. https://doi.org/10.3947/ic.2013.45.3.272

피인용 문헌

  1. Infection Complications in Hematopoietic Stem Cells Transplant Recipients: Do Genetics Really Matter? vol.9, pp.None, 2018, https://doi.org/10.3389/fmicb.2018.02317
  2. Implementation of Hospital Policy for Healthcare Workers and Patients Exposed to Varicella-Zoster Virus vol.33, pp.36, 2018, https://doi.org/10.3346/jkms.2018.33.e252
  3. Concise Review: Cheating Death for a Better Transplant vol.36, pp.11, 2018, https://doi.org/10.1002/stem.2901
  4. Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation : A PRISMA-compliant meta-analysis vol.98, pp.8, 2018, https://doi.org/10.1097/md.0000000000014474
  5. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy vol.20, pp.11, 2018, https://doi.org/10.3390/ijms20112666
  6. Reactivation and dynamics of cytomegalovirus and Epstein‐Barr virus after rabbit antithymocyte globulin and cyclosporine for aplastic anemia vol.103, pp.4, 2018, https://doi.org/10.1111/ejh.13308
  7. Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper vol.11, pp.None, 2020, https://doi.org/10.3389/fimmu.2020.01648
  8. Prospective evaluation of clinical symptoms of chemotherapy‐induced oral mucositis in adult patients with acute leukemia: A preliminary study vol.6, pp.1, 2018, https://doi.org/10.1002/cre2.253
  9. Characteristics and risk factors for mortality of invasive non‐Aspergillus mould infections in patients with haematologic diseases: A single‐centre 7‐year cohort study vol.63, pp.3, 2018, https://doi.org/10.1111/myc.13038
  10. Successful prevention and screening strategies for COVID‐19: focus on patients with haematologic diseases vol.190, pp.1, 2018, https://doi.org/10.1111/bjh.16818
  11. Viral Respiratory Infections in Hematological Patients vol.9, pp.3, 2018, https://doi.org/10.1007/s40121-020-00313-6
  12. Infectious disease in hematopoietic stem cell transplantation vol.8, pp.None, 2021, https://doi.org/10.1177/20499361211005600
  13. Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach vol.11, pp.None, 2021, https://doi.org/10.3389/fimmu.2020.611566
  14. Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (C vol.23, pp.4, 2021, https://doi.org/10.1111/tid.13611
  15. Oral shedding of CMV and HSV‐1 in hematopoietic stem cell transplantation patients vol.27, pp.6, 2018, https://doi.org/10.1111/odi.13690
  16. Is it time to reconsider prophylactic antimicrobial use for hematopoietic stem cell transplantation? a narrative review of antimicrobials in stem cell transplantation vol.19, pp.10, 2018, https://doi.org/10.1080/14787210.2021.1902304
  17. The Impact of NLRP3 Activation on Hematopoietic Stem Cell Transplantation vol.22, pp.21, 2018, https://doi.org/10.3390/ijms222111845
  18. MiR-181a and -b expression in acute lymphoblastic leukemia and its correlation with acute graft-versus-host disease after hematopoietic stem cell transplantation, COVID-19 and torque teno viruses vol.32, pp.4, 2018, https://doi.org/10.1007/s13337-021-00743-x
  19. Prevalence and clinical course of upper airway respiratory virus infection in critically ill patients with hematologic malignancies vol.16, pp.12, 2018, https://doi.org/10.1371/journal.pone.0260741